<DOC>
	<DOCNO>NCT00855764</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety paclitaxel give weekly patient advance recurrent head neck cancer</brief_summary>
	<brief_title>Late Phase II Study Weekly Paclitaxel ( BMS-181339 ) Patients With Advanced Recurrent Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Give write voluntary informed consent . Patients cytologically histopathologically confirm head neck cancer ( except thyroid cancer ) Patients locally advanced head neck cancer pretreated surgery and/or radiotherapy ( plus minus one chemotherapy regimen ) suitable radical local treatment patient distant metastasis may receive one chemotherapy regimen Patients must measurable disease ( lesion ( ) large diameter 10 mm ) Patients 4 week longer interval completion previous therapy . ( 2 week antimetabolites , Biological Response Modifiers ( BRM ) , Bisphosphonates brain bone irradiation /among radiotherapy/ ) . All reversible residual effect previous therapy resolve stabilized best degree , reasonably expect . Performance Status 0 2 Patients normal major organ function ( hematologic , hepatic renal , etc . ) meet list requirement time evaluation do within 2 week prior schedule first drug administration date Neutrophil count : ≤ 2,000/uL Platelet count : ≤ 100,000/uL Hemoglobin : ≤ 9.0g/dL AST : &lt; 100 IU/L ALT : &lt; 100 IU/L Total bilirubin : ≤ 1.5 mg/dL Serum creatinine : ≤ 1.5 mg/dL Patients expect survival period least 2 month study initiation . Men Women , age range 20 year old less 75 year . Women childbearing potential ( WOCBP ) unwilling unable use acceptable method avoid pregnancy entire study period 4 week study Women pregnant breastfeed Women positive pregnancy test enrollment prior study drug administration Sexually active fertile men use effective method birth control entire study period 8 week study Patients CNS metastasis associate clinical symptom , and/or associate surround edema CT scan MRI , require concomitant therapy steroid anticonvulsant Patients active second cancer ( synchronous second cancer diseasefree interval previous second primary cancer current cancer le 5 year ) Patients serious , uncontrolled medical illness ( i.e. , serious cerebrovascular disorder , uncontrolled hypertension diabetes mellitus , severe infection active gastric ulcer , etc . ) , acute inflammatory disease , etc . Patients interstitial pneumonia pulmonary fibrosis chest CTscan clinical symptom ( e.g. , fever , cough , shortness breath dyspnea ) Patients body cavity fluid retention require treatment ( intervention ) . However , show reaccumulation pleural effusion 2 week longer without use chemotherapy drug ( BRM include ) post thoracentesis chest tube drainage eligible enrollment . In addition , water suction pericardial effusion shall ineligible enrollment Patients meet one follow criterion ; Either myocardial infarction anginal attack within 6 month prior study participation Medical history congestive heart failure Arrhythmia require treatment Conduction abnormality ( Left bundlebranch block , Class II atrioventricular [ AV ] block ) Patients grade 1 peripheral neuropathy grade NCICTC version 2.0 criterion Patients history hypersensitivity due administration drug contain polyoxyethylene castor oil ( Cremophor EL ) ( e.g. , cyclosporine ) , harden castor oil ( e.g. , vitamin preparation injection , etc . ) Patients previous therapy taxanes ( e.g. , paclitaxel , docetaxel ) Patients receive investigational agent within 4 week prior study participation Patients compulsorily detain legal reason treatment either psychiatric physical ( e.g. , infectious disease ) illness Patients n't accept use supportive therapy , i.e. , blood transfusion anemia</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>